0.01 for all). In the cells with stable transfection, the secretion of HBsAg and HBeAg into the supernatant was significantly inhibited in all three transfection groups (P < 0.01 for all, vs negative control). The copies of HBV DNA were inhibited by 33.4% ± 3.0%, 60.8% ± 2.3% and 70.1% ± 3.3%, respectively. CONCLUSION: In HepG2.2.15 cells, HBV replication and expression could be inhibited by artificial microRNA targeting the HBV S coding region. Vector-based artificial microRNA could be a promising therapeutic approach for chronic HBV infection.
INTRODUCTIONRNA interference (RNAi) has become a new promising approach to develop effective antiviral drugs in recent years, including hepatitis C vir us (HCV), human immunodeficiency virus (HIV), poliovirus and hepatitis B vir us (HBV) [1][2][3] . For HBV, RNAi was shown to have impressive inhibitory effects against viral gene transcription and expression [4][5][6][7] . One recent study further demonstrated the viral clearance from the liver of transgenic mice by RNAi targeted HBV [8] , which sheds light on the use of RNAi in HBV gene therapy.HBV replication and gene expression can be strongly inhibited with virus specific siRNA treatment. However, the high sequence specificity of siRNAs, combined with prolonged treatment, promoted the emergence of siRNA-resistant virus variants. Selection of RNAi
RESULTS:The efficiency of transient transfection of the vectors into 2.2.15 cells was 55%-60%. All the vectors had significant inhibition effects on HBsAg and HBeAg at 72 h and 96 h after transfection (P < 0.01 for all). The secretion of HBsAg and HBeAg into the supernatant was inhibited by 49.8% ± 4.7% and 39.9% ± 6.7%, respectively, at 72 h in amiRNA-HBV-S608 plasmid transfection group. The copy of HBV DNA within culture supernatant was also significantly decreased at 72 h and 96 h after transfection (P < escape mutants has been reported in vitro for HIV, HCV and HBV [9][10][11] . These findings indicate that the antiviral properties of specific siRNAs targeted virus are not as effective as expected.RNAi can be triggered by small RNA molecules such as siRNA and microRNAs (miRNAs). MiRNAs endogenously expressed small ssRNA sequences of about 22 nucleotides in length, which naturally direct gene silencing through components shared with the RNAi pathway [12] . The mature miRNAs regulate gene expression by mRNA cleavage or translational repression [13,14] . Compared with siRNA, miRNA still can play a translational repression role when miRNAs partially complement with the target gene. Because of the flexibility of miRNA in binding with partially complementary mRNA targets, miRNA can serve as an anti-virus drug or vaccine to achieve a breakthrough in the treatment of virus mutation. Moreover, since miRNAs are single-stranded molecules insensitive to interferon systems, the utilization of this Pol-Ⅱ-mediated miRNA generation can be safe both in vitro and in vivo without the cytotoxic effects of dsRNAs and siRNAs [15] . These findings indicate that miRNA mediated RNAi can be used...